NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Thyrocare to Hold 26th AGM on June 30; Sets June 23 as Record Date for Final Dividend
Thyrocare Technologies has scheduled its 26th Annual General Meeting (AGM) for June 30, 2026, to discuss the FY 2025-26 Annual Report. The company has fixed June 23, 2026, as the record date for determining shareholder eligibility for the final dividend. Shareholders can participate in remote e-voting between June 26 and June 29, 2026. Dividend payments are expected to be processed on or before July 29, 2026.
முக்கிய அம்சங்கள்
26th Annual General Meeting scheduled for June 30, 2026, at 11:00 A.M. IST.Record date for final dividend eligibility is Tuesday, June 23, 2026.Dividend payment to be completed on or before Wednesday, July 29, 2026.E-voting period starts June 26, 2026, and ends June 29, 2026.Annual Report for FY 2025-26 and AGM Notice have been made available via digital links.
👀 கவனிக்க வேண்டியவை
Investors seeking the final dividend should ensure they hold shares by the June 23 record date. Shareholders are also encouraged to review the Annual Report to evaluate the company's financial health and strategic direction.
Thyrocare FY26 Revenue Grows 21% to ₹829 Cr; PAT Surges 79% to ₹163 Cr; AGM on June 30
Thyrocare Technologies delivered a robust performance in FY 2025-26, with revenue from operations increasing 21% YoY to ₹829.04 crore. Profit After Tax (PAT) witnessed a massive 79% jump to ₹162.85 crore, driven by operational efficiencies and network expansion. The company expanded its lab footprint to 41 locations and its test menu to over 1,275 tests. Additionally, the company declared a dividend of ₹9.33 per share (restated for the 2:1 bonus issue) and successfully integrated Think Health for home ECG services.
முக்கிய அம்சங்கள்
Revenue from operations grew 21% YoY to ₹829.04 crore in FY26 compared to ₹687.35 crore in FY25.Profit After Tax (PAT) surged by 79% to ₹162.85 crore, up from ₹90.75 crore in the previous year.Expanded laboratory network to 41 labs (including 7 new labs) and increased test menu to 1,275+ tests.EBITDA increased by 34% YoY to ₹255.88 crore with a significant improvement in margins.Proposed dividend of ₹9.33 per share, adjusted for the 2:1 bonus issue completed during the fiscal year.
👀 கவனிக்க வேண்டியவை
Investors should note the strong recovery in profitability and aggressive network expansion. The company's shift toward specialized diagnostics and home-based services like ECG makes it a competitive player in the diagnostic sector; hold for long-term growth.
Thyrocare Promoter Docon Technologies Reports 60.93% Total Shareholding Pledged in FY26 Disclosure
Docon Technologies, the promoter of Thyrocare, has filed its annual disclosure under SEBI Takeover Regulations for the financial year ended March 31, 2026. The filing confirms that the promoter's entire 60.93% stake in the company remains encumbered. Notable activity during the year included a pledge modification following a 2:1 bonus issue in December 2025, which brought the total pledged shares to 9,69,69,696. This disclosure is a routine compliance measure to ensure transparency regarding promoter share encumbrances.
முக்கிய அம்சங்கள்
Promoter Docon Technologies and API Holdings confirm 60.93% of total share capital is pledged.A 2:1 bonus issue in December 2025 led to the encumbrance of 6.46 crore additional shares.The total number of shares under pledge stands at 9,69,69,696 as of March 31, 2026.The filing confirms no new undisclosed encumbrances were created during the 2025-26 financial year.
👀 கவனிக்க வேண்டியவை
Monitor the high promoter pledge (100% of their stake) as a risk factor for potential volatility. No immediate action is needed as this is a routine regulatory confirmation of existing encumbrances.
Thyrocare reported a robust 21% YoY consolidated revenue growth for FY26, supported by a 23% increase in test volumes to 210 million. The specialized 'Jaanch' segment showed exceptional growth of 66% in Q4, while the flagship 'Aarogyam' brand grew 20%. Despite a slight dip in the partnership segment's Q4 growth to 23% due to a high base effect of INR 4 crore from the previous year, the company expanded its network to 10,800 franchisees and 41 labs globally. Strategic forays into genomics and the African market (Tanzania) signal a shift towards high-margin specialty diagnostics and geographic diversification.
முக்கிய அம்சங்கள்
Consolidated revenue grew 21% YoY in FY26, with Q4 revenue increasing by 20% YoY.Processed 210 million tests in FY26 (up 23% YoY) and served 19.2 million patients (up 15% YoY).The specialized 'Jaanch' portfolio surged 66% YoY in Q4, reflecting a shift toward disease-specific testing.Active franchisee network reached a record 10,800, while the lab network expanded to 41 locations including Tanzania.Maintained Six Sigma quality levels with complaints reduced to 3.06 per million tests and a turnaround time of 3.43 hours.
👀 கவனிக்க வேண்டியவை
Investors should monitor the scaling of the high-margin genomics and specialty segments, which are expected to drive future profitability. The company's expansion into Africa and its dominant B2B partnership growth make it a strong contender in the organized diagnostic space.
Thyrocare Declares ₹7 Final Dividend and ₹5.5 Cr Investment in Subsidiary
Thyrocare's board has recommended a final dividend of ₹7.00 per share, bringing the total dividend for FY26 to ₹9.33 per share post-bonus adjustment. The company is investing up to ₹5.50 crore in its wholly-owned subsidiary, Think Health Diagnostics, to bolster its diagnostic capabilities. Leadership remains stable with the re-appointment of Rahul Franklin Guha as MD & CEO for a five-year term. Furthermore, the company is broadening its business scope via MOA amendments to include digital healthcare platforms and allied services.
முக்கிய அம்சங்கள்
Recommended a final dividend of ₹7.00 per equity share for FY 2025-26.Total FY26 dividend stands at ₹9.33 per share post-bonus adjustment.Approved equity infusion of up to ₹5.50 crore in Think Health Diagnostics Private Limited.Re-appointed Rahul Franklin Guha as MD & CEO for a 5-year term starting May 2027.Proposed MOA alteration to expand business into digital platforms and broader healthcare services.
👀 கவனிக்க வேண்டியவை
Investors should take note of the consistent dividend payout and leadership continuity as positive indicators of corporate health. The strategic expansion into digital diagnostic platforms and allied services suggests a long-term growth roadmap beyond traditional pathology.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Thyrocare Recommends Rs 7 Dividend, Re-appoints CEO, and Invests Rs 5.5 Cr in Subsidiary
Thyrocare's board has recommended a final dividend of Rs 7.00 per share, bringing the total FY26 dividend to Rs 9.33 per share post-bonus adjustment. The company is re-appointing Rahul Franklin Guha as CMD & CEO for another five-year term and has approved a fresh investment of up to Rs 5.50 crore in its subsidiary, Think Health Diagnostics. Additionally, the company is broadening its Memorandum of Association to include a wider range of healthcare and digital diagnostic services. Significant board reshuffling also occurred with two resignations and two new appointments of non-executive directors.
முக்கிய அம்சங்கள்
Recommended final dividend of Rs 7.00 per share; total FY26 dividend stands at Rs 9.33 post-bonus adjustmentRe-appointment of Rahul Franklin Guha as CMD & CEO for a 5-year term starting May 2027Approved investment of up to Rs 5.50 crore in wholly-owned subsidiary Think Health Diagnostics Private LimitedAppointment of Price Waterhouse Chartered Accountants LLP as Statutory Auditors for a 5-year termProposed MOA changes to broaden business scope into digital platforms and allied healthcare services
👀 கவனிக்க வேண்டியவை
Investors should find the dividend payout and leadership continuity as positive indicators of stability. The strategic expansion of the business scope via MOA amendments suggests a long-term growth plan in the digital healthcare ecosystem.
Thyrocare Recommends ₹7 Final Dividend; Total FY26 Dividend at ₹9.33 per Share
Thyrocare Technologies has recommended a final dividend of ₹7 per equity share for FY 2025-26, bringing the total dividend for the year to ₹9.33 per share post-bonus adjustment. The company also announced a ₹5.50 crore investment in its subsidiary, Think Health Diagnostics, to expand its diagnostic footprint. Significant leadership updates include the five-year re-appointment of Rahul Guha as CMD & CEO and the appointment of Price Waterhouse as Statutory Auditors. Furthermore, the company is amending its Memorandum of Association to broaden its scope in the healthcare and diagnostic ecosystem.
முக்கிய அம்சங்கள்
Recommended final dividend of ₹7.00 per equity share for FY 2025-26Total dividend for FY26 aggregates to ₹9.33 per share after post-bonus adjustmentApproved investment of up to ₹5.50 crore in wholly-owned subsidiary Think Health DiagnosticsRe-appointed Rahul Franklin Guha as CMD & CEO for a 5-year term starting May 2027Appointed Price Waterhouse Chartered Accountants LLP as Statutory Auditors for a 5-year term
👀 கவனிக்க வேண்டியவை
Investors should view the consistent dividend payout and leadership continuity as positive signs of stability. The expansion of the company's business objects and investment in subsidiaries suggest a focus on long-term growth in the diagnostic sector.
Thyrocare Q4 FY26 Standalone Net Profit Surges 98.5% YoY to ₹43.58 Cr; Revenue Up 21%
Thyrocare Technologies reported a robust performance for the quarter ended March 31, 2026, with standalone revenue growing 21.2% YoY to ₹210.67 crore. Net profit for the quarter nearly doubled, rising 98.5% YoY to ₹43.58 crore, reflecting strong operational leverage. For the full financial year 2026, the company's net profit reached ₹148.81 crore, a significant 55.4% increase over the previous year's ₹95.78 crore. The company maintained an unmodified audit opinion, signaling healthy financial reporting standards.
முக்கிய அம்சங்கள்
Standalone Revenue for Q4 FY26 rose 21.2% YoY to ₹210.67 crore from ₹173.87 crore.Net Profit for Q4 FY26 jumped 98.5% YoY to ₹43.58 crore compared to ₹21.95 crore in the same period last year.Full-year FY26 Net Profit increased by 55.4% to ₹148.81 crore against ₹95.78 crore in FY25.Annual Revenue from operations grew 22.3% to ₹774.27 crore in FY26.Basic EPS for the full year improved significantly to ₹9.36 from ₹5.98 in the previous fiscal year.
👀 கவனிக்க வேண்டியவை
The strong double-digit growth in revenue and substantial margin expansion leading to a profit surge are very positive indicators for the stock. Investors should consider the company's improved profitability and operational efficiency as a sign of strengthening market position in the diagnostic sector.
Thyrocare Q4FY26 PAT Surges 128% YoY to ₹48.7 Cr; Revenue Up 20%
Thyrocare reported a strong Q4FY26 with consolidated revenue growing 20% YoY to ₹223.95 crore, driven by a 21% rise in the pathology segment. Profit After Tax (PAT) saw a massive jump of 128% YoY to ₹48.70 crore, while EBITDA margins improved to 34% from 31% in the previous year's quarter. For the full year FY26, the company achieved a revenue of ₹829.04 crore and a PAT of ₹162.85 crore, reflecting robust volume growth of 23%. The company is also diversifying into high-margin specialty diagnostics like genomics and allergy testing.
முக்கிய அம்சங்கள்
Consolidated Q4FY26 revenue grew 20% YoY to ₹223.95 Cr, while FY26 revenue rose 21% to ₹829.04 Cr.Q4FY26 PAT surged 128% YoY to ₹48.70 Cr; FY26 PAT grew 81% YoY to ₹162.85 Cr.Test volumes increased by 29% YoY in Q4 to 59 million tests, maintaining industry volume leadership.Reported EBITDA grew 31% YoY to ₹75.09 Cr in Q4, with margins expanding to 34%.Expansion into specialty diagnostics with 250+ allergy SKUs and launch of Non-invasive Pre-Natal Testing (NIPT).
👀 கவனிக்க வேண்டியவை
Investors should view these results positively as the company demonstrates strong operating leverage and volume-led growth. The entry into high-value genomics and specialty testing provides a long-term catalyst for margin improvement.
Thyrocare Infuses Additional USD 475,000 in Tanzania Subsidiary via CCPS
Thyrocare Technologies has invested an additional USD 475,000 (approx. INR 4.33 Crores) into its subsidiary, Thyrocare Laboratories (Tanzania) Limited. This capital infusion was executed through Compulsorily Convertible Irredeemable Preference Shares (CCPS) to support working capital and business operations. The total investment in the Tanzanian venture now reaches approximately INR 10.02 Crores, against a board-approved limit of INR 15 Crores. While the subsidiary is scaling with a turnover of INR 1.84 Crores in 2025, it currently reports a negative net worth of INR 0.32 Crores.
முக்கிய அம்சங்கள்
Additional investment of USD 475,000 (INR 4.33 Crores) via subscription to CCPS.Total cumulative investment in the Tanzanian subsidiary now stands at INR 10.02 Crores.Thyrocare Tanzania reported a turnover of INR 1.84 Crores for the year ended December 31, 2025.The company maintains a 57.25% equity stake and 100% CCPS holding in the joint venture.Board approval allows for a total investment of up to INR 15 Crores in one or more tranches.
👀 கவனிக்க வேண்டியவை
Investors should monitor the turnaround and scaling of the Tanzanian operations, as the subsidiary currently has a negative net worth. While the investment amount is small relative to Thyrocare's balance sheet, it reflects the company's commitment to international expansion.
Thyrocare Q3 FY26: Revenue Grows 18% YoY; Pathology Up 20% with Record 10,300 Franchisees
Thyrocare reported a strong Q3 FY26 with consolidated revenue growing 18% YoY, led by a 20% surge in the pathology segment. The company processed 49.6 million tests, a 22% increase, and expanded its active franchisee base to a record 10,300 partners. While the core franchisee business grew 12%, the partnership and insurance segments saw robust growth of 39% and 70% respectively. Management also highlighted achieving Six Sigma quality standards and the appointment of new leadership to drive further expansion.
முக்கிய அம்சங்கள்
Consolidated revenue grew 18% YoY, with the core pathology business increasing by 20%.Total tests processed rose 22% YoY to 49.6 million, serving 4.5 million patients (up 14% YoY).Active quarterly franchisee base reached an all-time high of 10,300, up from 9,165 in the previous year.Partnership business revenue jumped 39% YoY, while the pre-policy medical checkup segment grew 70%.Achieved Six Sigma quality benchmark with 3.2 complaints per million tests, a 43% YoY improvement.
👀 கவனிக்க வேண்டியவை
Investors should monitor the scaling of the partnership business and the path to breakeven for the Tanzania operations. The strong volume growth and record franchisee additions indicate robust market share gains and operational efficiency.
Thyrocare Q3 FY26 Results: Consolidated PAT Jumps 47% YoY to ₹27.9 Cr; Revenue Up 18%
Thyrocare Technologies reported a strong performance for Q3 FY26, with consolidated revenue growing 18% YoY to ₹195.5 crore. The company's profitability saw a significant boost as Reported EBITDA rose 38% YoY to ₹57.6 crore and Profit After Tax (PAT) surged 47% to ₹27.9 crore. Operational metrics remained robust with a 22% increase in tests conducted (49.6 million) and a 14% rise in patient volume. While the radiology segment saw a 7% revenue decline due to strategic exits from non-profitable centers, the core pathology business and partnership segments (up 39%) drove overall growth.
முக்கிய அம்சங்கள்
Consolidated Revenue increased 18% YoY to ₹195.53 crore, driven by 20% growth in standalone pathology.Reported EBITDA grew 38% YoY to ₹57.64 crore, with margins expanding from 25% to 29%.Net Profit (PAT) surged 47% YoY to ₹27.91 crore; excluding exceptional items, PAT grew 80% to ₹34.07 crore.Operational volume reached 49.6 million tests (+22% YoY) and 4.5 million patients (+14% YoY).Partnership revenue grew by 39% YoY, while the active franchisee base expanded by 12% to approximately 10,300.
👀 கவனிக்க வேண்டியவை
The company demonstrates strong operational leverage and volume-led growth in its core pathology segment. Investors should maintain a positive outlook given the margin expansion and robust partnership growth, while monitoring the impact of the new brand ambassador on retail market share.
Thyrocare Q3 FY26 Net Profit Rises 37% YoY to ₹26.15 Cr; Revenue Up 20%
Thyrocare Technologies reported a strong performance for the quarter ended December 31, 2025, with revenue from operations growing 19.6% YoY to ₹182.48 crore. Net profit increased by 36.9% YoY to ₹26.15 crore, even after accounting for an exceptional charge of ₹5.97 crore related to new labor code compliance and capital restructuring. The company successfully executed a 2:1 bonus issue during the quarter, which resulted in the allotment of over 10.61 crore new shares. For the nine-month period, the company has shown robust growth with a net profit of ₹105.23 crore compared to ₹73.96 crore in the previous year.
முக்கிய அம்சங்கள்
Revenue from operations increased 19.6% YoY to ₹182.48 crore from ₹152.55 crore.Net Profit grew 36.9% YoY to ₹26.15 crore; 9M FY26 profit stands at ₹105.23 crore.Exceptional item of ₹5.97 crore includes ₹4.01 crore for gratuity adjustments under New Labour Codes.Successfully completed a 2:1 bonus share allotment on December 1, 2025, increasing paid-up capital to ₹159.16 crore.Restated Basic EPS for the quarter stands at ₹1.64 compared to ₹1.18 in the year-ago period.
👀 கவனிக்க வேண்டியவை
Investors should take note of the strong double-digit growth in both revenue and profitability, indicating improved operational efficiency. The completion of the bonus issue and the one-time nature of the labor code impact suggest a clean slate for future earnings growth.
Thyrocare Appoints Industry Veteran Rajdeep Panwar as Chief Commercial Officer
Thyrocare Technologies has appointed Mr. Rajdeep Panwar as its Chief Commercial Officer, effective January 05, 2026. Mr. Panwar brings over 21 years of deep industry experience, having held leadership roles at major diagnostic players including Dr. Lal PathLabs, Apollo Diagnostics, and Medanta Labs. His expertise in P&L management and laboratory network expansion is expected to drive the company's commercial growth and market penetration. This appointment strengthens the senior management team as the company looks to scale its diagnostic operations across India.
முக்கிய அம்சங்கள்
Appointment of Mr. Rajdeep Panwar as Chief Commercial Officer effective January 05, 2026Mr. Panwar brings over 21 years of experience in healthcare and diagnostics industry leadershipPrevious experience includes Director at Medanta Labs and roles at Apollo Diagnostics and Dr. Lal PathLabsExpertise spans P&L management, digital diagnostics, and large-scale laboratory network expansionThe appointment was approved by the Board via circular resolution on January 05, 2026
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive step in strengthening Thyrocare's commercial leadership; monitor for improvements in market share and network expansion in upcoming quarters.
Thyrocare Appoints Dr. Ramesh Kinha as Chief Operating Officer
Thyrocare Technologies has appointed Dr. Ramesh Kinha as its Chief Operating Officer (COO) effective December 18, 2025. Dr. Kinha is a seasoned professional with over 17 years of experience in the healthcare and diagnostics sector, having previously served as Group Director at Vijaya Diagnostic Centre. His extensive background includes leadership roles at major industry players such as Metropolis Healthcare and SRL Ltd. This appointment is expected to strengthen Thyrocare's operational leadership and strategic execution in the competitive diagnostics market.
முக்கிய அம்சங்கள்
Dr. Ramesh Kinha appointed as Chief Operating Officer effective December 18, 2025Brings over 17 years of experience across major diagnostic firms including Metropolis, SRL, and Vijaya DiagnosticHolds an MBBS, MD in Pathology, and senior management certifications from IIM Nagpur and ISBExpertise spans laboratory services, quality assurance, and organization-wide strategic operations
👀 கவனிக்க வேண்டியவை
Investors should monitor how Dr. Kinha's operational expertise impacts the company's efficiency and service quality. This is a positive leadership addition given his deep industry experience and medical background.
Thyrocare Allots 10.61 Crore Bonus Equity Shares in 2:1 Ratio
Thyrocare Technologies has successfully allotted 10,61,07,794 bonus equity shares to eligible shareholders as of the record date, November 28, 2025. The bonus issue was executed in a 2:1 ratio, meaning shareholders received two new shares for every one share held. This corporate action has increased the company's total paid-up share capital from Rs. 53.05 crore to Rs. 159.16 crore. The total number of outstanding equity shares has tripled to 15,91,61,691 shares.
முக்கிய அம்சங்கள்
Allotment of 10,61,07,794 fully paid-up bonus equity shares of Rs. 10 eachBonus ratio of 2:1 implemented for all eligible members as of November 28, 2025Total paid-up share capital increased from 5,30,53,897 to 15,91,61,691 equity sharesPost-bonus paid-up capital value stands at Rs. 159,16,16,910New shares rank pari-passu in all respects with existing equity shares
👀 கவனிக்க வேண்டியவை
Investors should account for the tripled share count in their portfolios and note that the stock price has adjusted to reflect the 2:1 bonus. No further action is required as the allotment is now complete.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
